Cochrane · systematic review · CD007572
Anti‐IL‐12/23p40 antibodies for induction of remission in Crohn's disease
MacDonald, JK, Nguyen, TM, Khanna, R, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 42.9%Moderate 4 · 28.6%High 4 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyBriakinumab compared to placebo for induction of remission in Crohn's disease
Population: induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) Briakinumab vs placebo | RR 0.86 [0.65, 1.14] | 1 study · 79 participants | Low Downgraded: imprecision |
Failure to induce clinical remission (Panaccione 2010) CDAI (≤150 points) Briakinumab vs placebo | RR 0.92 [0.83, 1.03] | 1 study · 230 participants | Low Downgraded: imprecision |
Failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point reduction) Briakinumab vs placebo | RR 0.65 [0.42, 0.99] | 1 study · 79 participants | Low Downgraded: imprecision |
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) Briakinumab vs placebo | RR 0.82 [0.67, 0.99] | 1 study · 230 participants | Moderate Downgraded: imprecision |
Adverse events (Panaccione 2010) Briakinumab vs placebo | RR 0.9 [0.75, 1.07] | 1 study · 230 participants | Moderate Downgraded: imprecision |
Serious adverse events (Panaccione 2010) Briakinumab vs placebo | RR 0.52 [0.17, 1.61] | 1 study · 246 participants | Low Downgraded: imprecision |
Withdrawals due to adverse event** (Pannaccione 2010) Briakinumab vs placebo | RR 0.69 [0.14, 3.31] | 1 study · 246 participants | Low Downgraded: imprecision |
Ustekinumab compared to placebo for induction of remission in Crohn's disease
Population: patients with induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to induce clinical remission CDAI (≤ 150) Ustekinumab vs placebo | RR 0.92 [0.88, 0.96] | 3 studies · 1320 participants | High |
Failure to induce clinical remission (6 mg/kg subgroup) CDAI (≤ 150) Ustekinumab vs placebo | RR 0.92 [0.87, 0.97] | 2 studies · 916 participants | Moderate Downgraded: inconsistency |
Failure to induce clinical response CDAI (≥100 point reduction) Ustekinumab vs placebo | RR 0.82 [0.77, 0.88] | 3 studies · 1320 participants | High |
Failure to induce clinical response (6 mg/kg subgroup) CDAI (≥100 point reduction) Ustekinumab vs placebo | RR 0.83 [0.77, 0.91] | 2 studies · 916 participants | High |
Adverse events Ustekinumab vs placebo | RR 0.97 [0.9, 1.04] | 4 studies · 2023 participants | High |
Serious adverse events Ustekinumab vs placebo | RR 0.83 [0.58, 1.2] | 4 studies · 2023 participants | Moderate Downgraded: imprecision |
Withdrawals due to adverse event Ustekinumab vs placebo | RR 0.44 [0.18, 1.05] | 2 studies · 657 participants | Low Downgraded: imprecision |
Briakinumab compared to placebo for induction of remission in Crohn's disease
Population: induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to induce clinical remission (Mannon 2004) CDAI (≤150 points) Briakinumab vs placebo | RR 0.86 [0.65, 1.14] | 1 study · 79 participants | Low Downgraded: imprecision |
Failure to induce clinical remission (Panaccione 2010) CDAI (≤150 points) Briakinumab vs placebo | RR 0.92 [0.83, 1.03] | 1 study · 230 participants | Low Downgraded: imprecision |
Failure to induce clinical response (Mannon 2004) CDAI ‐ (≥100 point reduction) Briakinumab vs placebo | RR 0.65 [0.42, 0.99] | 1 study · 79 participants | Low Downgraded: imprecision |
Failure to induce clinical response (Panaccione 2010) CDAI ‐ (≥100 point reduction) Briakinumab vs placebo | RR 0.82 [0.67, 0.99] | 1 study · 230 participants | Moderate Downgraded: imprecision |
Adverse events (Panaccione 2010) Briakinumab vs placebo | RR 0.9 [0.75, 1.07] | 1 study · 230 participants | Moderate Downgraded: imprecision |
Serious adverse events (Panaccione 2010) Briakinumab vs placebo | RR 0.52 [0.17, 1.61] | 1 study · 246 participants | Low Downgraded: imprecision |
Withdrawals due to adverse event** (Pannaccione 2010) Briakinumab vs placebo | RR 0.69 [0.14, 3.31] | 1 study · 246 participants | Low Downgraded: imprecision |
Ustekinumab compared to placebo for induction of remission in Crohn's disease
Population: patients with induction of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to induce clinical remission CDAI (≤ 150) Ustekinumab vs placebo | RR 0.94 [0.88, 1.01] | 2 studies · 579 participants | Moderate |
Failure to induce clinical response CDAI (≥100 point reduction) Ustekinumab vs placebo | RR 0.79 [0.71, 0.89] | 2 studies · 579 participants | Moderate Downgraded: imprecision |
Adverse events Ustekinumab vs placebo | RR 0.92 [0.83, 1.03] | 2 studies · 657 participants | High |
Serious adverse events Ustekinumab vs placebo | RR 0.81 [0.44, 1.49] | 2 studies · 657 participants | Low Downgraded: imprecision |
Withdrawals due to adverse event Ustekinumab vs placebo | RR 0.44 [0.18, 1.05] | 2 studies · 657 participants | Low Downgraded: imprecision |